Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
Public ClinicalTrials.gov record NCT03257163. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Preoperative Pembrolizumab for Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer Followed by Chemotherapy and Chemoradiation With Pembrolizumab
Study identification
- NCT ID
- NCT03257163
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Enrollment
- 40 participants
Conditions and interventions
Conditions
- Epstein-Barr Virus Positive
- Gastric Adenocarcinoma
- Mismatch Repair Protein Deficiency
- Stage IB Gastric Cancer AJCC v7
- Stage II Gastric Cancer AJCC v7
- Stage IIA Gastric Cancer AJCC v7
- Stage IIB Gastric Cancer AJCC v7
- Stage III Gastric Cancer AJCC v7
- Stage IIIA Gastric Cancer AJCC v7
- Stage IIIB Gastric Cancer AJCC v7
- Stage IIIC Gastric Cancer AJCC v7
Interventions
- Capecitabine Drug
- Laboratory Biomarker Analysis Other
- Pembrolizumab Biological
- Radiation Therapy Radiation
Drug · Other · Biological + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 28, 2017
- Primary completion
- Aug 30, 2026
- Completion
- Dec 30, 2026
- Last update posted
- Jan 19, 2026
2017 – 2026
United States locations
- U.S. sites
- 4
- U.S. states
- 3
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Emory University | Atlanta | Georgia | 30308 | — |
| RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton | Hamilton | New Jersey | 08690 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03257163, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 19, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03257163 live on ClinicalTrials.gov.